<DOC>
	<DOCNO>NCT00172185</DOCNO>
	<brief_summary>The purpose clinical study evaluate long-term safety efficacy daily administration teduglutide .</brief_summary>
	<brief_title>Safety Efficacy Study Teduglutide Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 ( NCT00081458 )</brief_title>
	<detailed_description>Teduglutide analog naturally occur human glucagon-like peptide-2 ( GLP-2 ) , peptide secrete L-cells distal intestine . GLP-2 known increase intestinal portal blood flow , inhibit gastric acid secretion . Teduglutide bind glucagon-like peptide-2 receptor locate intestinal subpopulation enteroendocrine cell , subepithelial myofibroblasts enteric neuron submucosal myenteric plexus . Activation receptor result local release multiple mediator include insulin-like growth factor ( IGF ) -1 , nitric oxide keratinocyte growth factor ( KGF ) . This multicenter , double-blind , international , Phase III trial treatment period 28 week . Subjects study receive teduglutide placebo protocol CL0600-004 ( NCT00081458 ) . These subject receive daily subcutaneous injection 0.05 milligram 0.10 milligram teduglutide per kilogram body weight . Subjects visits every 4 6 week assess parenteral nutrition ( PN ) reduction follow-up period 4 week duration subject complete protocol , enter long-term safety extension protocol CL0600-010 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>At dose week 24 protocol CL0600004 ( NCT00081458 ) , subject review participation study . Subjects meet follow criterion enrol study : Signed date informed consent form ( ICF ) participate studyrelated procedure perform Completion protocol CL0600004 ( NCT00081458 ) History cancer clinically significant lymphoproliferative disease few 5 year document diseasefree state History alcohol drug abuse ( within previous year ) Prior use native glucagonlike peptide 2 ( GLP2 ) within 3 month screen visit Pregnant lactate woman Any condition circumstance , investigator 's opinion would put subject undue risk , prevent completion study , interfere analysis study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Short Bowel Syndrome</keyword>
	<keyword>Parenteral Nutrition</keyword>
	<keyword>SBS</keyword>
	<keyword>Teduglutide</keyword>
</DOC>